NCT05482789View on ClinicalTrials.gov

Exenatide Pharmacokinetics and Pharmacodynamics in Gestational Diabetes

PHASE4RecruitingINTERVENTIONAL

Enrollment

13

Participants

Timeline

Start Date

April 12, 2023

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions

Gestational Diabetes

Interventions

DRUG

Exenatide

10 microgram injected sub-cutaneously once

Trial Locations (1)

15213

RECRUITING

Magee Womens Hospital of UPMC, Pittsburgh

All Listed Sponsors

lead

Maisa N. Feghali, MD

OTHER